Return to homepagePandemic Pact

Kaiser Washington Vaccine and Treatment Evaluation Unit - DMID 21-0004

  • Funded by National Institutes of Health (NIH)
  • Total publications:0 publications

Grant number: 3UM1AI148373-03S6

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2022
    2024

  • Known Financial Commitments (USD)

    $2,114,527

  • Funder

    National Institutes of Health (NIH)

  • Principal Investigator

    LISA JACKSON

  • Research Location

    United States of America

  • Lead Research Institution

    KAISER FOUNDATION RESEARCH INSTITUTE

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase II

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    WomenPregnant women

  • Occupations of Interest

    Unspecified

Abstract

The 21-0004 protocol will evaluate the safety and immunogenicity of SARS-CoV-2 administered during pregnancy or postpartum. The Seattle Children's Research Institute, a subcontractor to the Kaiser Washington VTEU, has been selected to perform SARS-CoV-2 pseudovirus neutralization assays for the 21-0004 trial. The NIH will provide funds for the assay work to the Kaiser Washington VTEU, which will then provide funds to the Seattle Children's Research Institute via the existing subcontract. Kaiser Washington is not a clinical site for the 21-0004 trial and the work of the subcontractor is the only involvement of Kaiser Washington in that trial.